Zynbrita a New Treatment Available for Relapsing Multiple Sclerosis

Web Exclusives - FDA Approvals, In the News

On May 27, 2016, the FDA approved daclizumab (Zinbryta; Biogen), a long-acting injection, for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab can be self-administered by the patient.  Daclizumab is recommended for patients who had an inadequate response to ≥2 drugs for MS, because of its safety profile.

Daclizumab was approved for relapsing MS based on 2 double-blind, controlled clinical trials that used 150 mg daclizumab, administered once monthly. The first trial compared daclizumab with interferon beta-1a (Avonex) in 1841 patients with relapsing MS. The daclizumab group had a 45% relapse reduction and a 54% reduction in new or enlarging T2- hyperintense lesions versus the interferon beta-1a group. The second study compared daclizumab with placebo in 412 patients with relapsing MS. Daclizumab had a 54% relapse reduction, a 57% reduction in disease progression, a 70% reduction in new or newly enlarging T2-hyperintense lesions, and a 69% reduction in new T1 Gd-enhancing lesions versus interferon beta-1a. Of note, 81% of patients using daclizumab were relapse free compared with 64% in the interferon beta-1a group.

The most common adverse events reported with daclizumab in the 2 studies included nasopharyngitis, upper respiratory tract infection, eczema, rash, influenza, dermatitis, depression, oropharyngeal pain, lymphadenopathy, and increased alanine aminotransferase levels.

Daclizumab was approved with a boxed warning about the serious risk for hepatic injury, including autoimmune hepatitis and other immune-mediated disorders. Transaminase and bilirubin levels should be evaluated before starting daclizumab therapy, and patients should be monitored monthly and up to 6 months after stopping therapy. Daclizumab is distributed through a Risk Evaluation and Mitigation Strategy program only.

Related Items
Tazverik First FDA-Approved Drug for Advanced Epithelioid Sarcoma Ineligible for Resection
February 2020 Vol 13, Special Issue published on February 25, 2020 in Drug Updates, FDA Approvals
Ayvakit First Targeted Therapy Approved for Gastrointestinal Stromal Tumors with PDGFRA Mutation
February 2020 Vol 13, Special Issue published on February 25, 2020 in Drug Updates, FDA Approvals
Enhertu, a Dual-Targeted Therapy, Approved for Metastatic HER2-Positive Breast Cancer
February 2020 Vol 13, Special Issue published on February 25, 2020 in Drug Updates, FDA Approvals
Padcev, a Novel Targeted Therapy, FDA Approved for Advanced or Metastatic Urothelial Cancer
February 2020 Vol 13, Special Issue published on February 25, 2020 in Drug Updates, FDA Approvals
Keytruda Indicated for BCG-Unresponsive High-Risk, Non–Muscle Invasive Bladder Cancer
February 2020 Vol 13, Special Issue published on February 25, 2020 in Drug Updates, FDA Approvals
Last modified: February 14, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME